减轻心肌缺血-再灌注损伤是临床治疗缺血性心血管疾病需要面对的重要问题。药物防治的基础研究通常忽略了临床患者实际所处的多种危险因素(如：肥胖、2型糖尿病、高血脂、高血压等)存在背景，导致药效无法在临床重现。肥胖、2型糖尿病是中国面临的巨大危机，因此在本项目研究中，我们拟在胰岛素抵抗背景下，研究稀有人参皂苷对缺血-再灌注心肌的保护作用。首先，我们从熟三七中分离获得高产率稀有人参皂苷，再从细胞、离体心脏和整体动物水平建立胰岛素抵抗模型及缺血/缺氧-再灌注/复氧模型，考察稀有人参皂苷在不同阶段给药对心肌的保护作用。然后，以胰岛素抵抗状态下心肌葡萄糖-脂肪酸循环（Randle cycle）调节和线粒体代谢稳态作为切入点，研究稀有人参皂苷对抗心肌缺血-再灌注损伤的作用环节和分子机制。本项目的顺利完成不仅为防治心肌缺血-再灌注损伤提供候选药，也可为其他相关新药研究提供借鉴。

Attenuating cardiac ischemia-reperfusion injury is an important issue to be considered in the clinic. However, the protective effects of many drugs used in the basic studies cannot re-appear in the clinic because of ignoring the sustaining presence of cardiovascular risk factors（such as obesity, type 2 diabetes, hyperlipoidemia and hypertension）facing the clinical subjects. China in the 21st is challenged by obesity and diabetes, therefore we try to study the protective role of rare ginsenosides in the prevention and treatment of cardiac ischemia-reperfusion injury and the underlying mechanisms in the setting of insulin resistance. We will first extract and purify the rare ginsenosides from steamed notogensing. Then, the cellular and animal insulin resistance and ischemia-reperfusion injury models will be prepared for the evaluation of the effect of rare ginsensides when used during different periods. Finally, we will try to study the pathways and molecular targets of the rare ginsenosides by focusing on glucose-fatty acid cycle (also called Randle cycle) and mitochondrial metabolic homeostasis. This work will provide not only a new candidate drug for the prevention and treatment of cardiac ischemia-reperfusion injury, but also some helpful experiences for other investigators.